US Patent Issued to Virion Therapeutics, The Wistar Institute on May 6 for "Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same" (California, Pennsylvania Inventors)

ALEXANDRIA, Va., June 10 -- United States Patent no. 12,290,561, issued on May 6, was assigned to Virion Therapeutics LLC (Newark, Del.) and The Wistar Institute (Philadelphia).

"Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same" was invented by Hildegund C J Ertl (Villanova, Pa.) and Colin Stephen Magowan (Bishop, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a...